Statins-From Fungi to Pharmacy

被引:21
作者
Sadowska, Anna [1 ]
Osinski, Patryk [2 ]
Roztocka, Alicja [2 ]
Kaczmarz-Chojnacka, Karolina [2 ]
Zapora, Ewa [3 ]
Sawicka, Diana [1 ]
Car, Halina [1 ]
机构
[1] Med Univ Bialystok, Dept Expt Pharmacol, Szpitalna 37, PL-15295 Bialystok, Poland
[2] Lazarski Univ, Students Pharmacol Club, Świeradowska 43, PL-02662 Warsaw, Poland
[3] Bialystok Tech Univ, Inst Forest Sci, Dept Silviculture & Forest Use, Wiejska 45E, PL-15351 Bialystok, Poland
关键词
statins; fungi; cholesterol; HMG-CoA reductase; HMG-COA REDUCTASE; COENZYME-A REDUCTASE; RED YEAST RICE; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HIV-INFECTED PATIENTS; LOW SERUM-CHOLESTEROL; C-REACTIVE PROTEIN; ASPERGILLUS-TERREUS; DOUBLE-BLIND; CARDIOVASCULAR-DISEASE;
D O I
10.3390/ijms25010466
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Statins have been used in the treatment of hyperlipidemia, both as monotherapy and in combination therapy. Natural fermentation processes of fungi such as Monascus spp., Penicillium spp., Aspergillus terreus, and Pleurotus ostreatus have given rise to natural statins. Compactin (mevastatin), the original naturally occurring statin, is the primary biotransformation substrate in the manufacturing process of marketed drugs. Statins are classified into natural, semi-synthetic derivatives of natural statins, and synthetic ones. Synthetic statins differ from natural statins in their structural composition, with the only common feature being the HMG-CoA-like moiety responsible for suppressing HMG-CoA reductase. Statins do not differ significantly regarding their pleiotropic and adverse effects, but their characteristics depend on their pharmacokinetic parameters and chemical properties. This paper focuses on describing the processes of obtaining natural statins, detailing the pharmacokinetics of available statins, divided into natural and synthetic, and indicating their pleiotropic effects.
引用
收藏
页数:25
相关论文
共 201 条
[91]   A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia [J].
Jeong, Han Saem ;
Hong, Soon Jun ;
Cho, Jin-Man ;
Han, Ki Hoon ;
Cha, Dong-Hun ;
Jo, Sang-Ho ;
Kang, Hyun-Jae ;
Choi, So-Yeon ;
Choi, Cheol Ung ;
Cho, Eun Jeong ;
Jeong, Young-Hoon ;
Gwon, Hyeon-Cheol ;
Kim, Byeong-Keuk ;
Lee, Sung Yun ;
Kim, Sang-Hyun ;
Ahn, Jeong Cheon ;
Hong, Young Joon ;
Kim, Woo-Shik ;
Woo, Seong-Ill ;
Park, Tae-Ho ;
Han, Kyoo-Rok .
CLINICAL THERAPEUTICS, 2022, 44 (10) :1310-1325
[92]   Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial) [J].
Jones, PH ;
Davidson, MH ;
Stein, EA ;
Bays, HE ;
McKenney, JM ;
Miller, E ;
Cain, VA ;
Blasetto, JW ;
STELLAR Study Grp .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (02) :152-160
[93]   The Controversies of Statin Therapy Weighing the Evidence [J].
Jukema, J. Wouter ;
Cannon, Christopher P. ;
de Craen, Anton J. M. ;
Westendorp, Rudi G. J. ;
Trompet, Stella .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (10) :875-881
[94]   Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia [J].
Jung, Hae Won ;
Kim, Chang-Yeon ;
Hong, Seung-Pyo ;
Bae, Han-Joon ;
Choi, Ji Yong ;
Ryu, Jae Kean ;
Lee, Jin-bae ;
Lee, Kyoung-Hoon ;
Han, Kyoo-Rok ;
Yang, Dong-Heon ;
Park, Chang-Gyu ;
Yu, Gheol-Woong ;
Rhee, Moo-Yong ;
Park, Sung-Ji ;
Hyon, Min-Su ;
Shin, Joon-Han ;
Hong, Bum-Kee ;
Jin, Han-Young ;
Lee, Sung-Yun ;
Seol, Sang-Hoon ;
Lee, Sang-Rok ;
Kim, Song-Yi ;
Lee, Kwang-Je ;
Cho, Eun-Joo ;
Nam, Chang-Wook ;
Park, Tae-Ho ;
Kim, Ung ;
Kim, Kee-Sik .
JOURNAL OF CLINICAL HYPERTENSION, 2023, 25 (09) :828-844
[95]   Improvement of synaptic plasticity and cognitive function in RASopathies-a monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial (SynCoRAS) [J].
Jung, Nikolai H. ;
Egert-Schwender, Silvia ;
Schossow, Beate ;
Kehl, Victoria ;
Wahllaender, Ute ;
Brich, Louisa ;
Janke, Viktoria ;
Blankenstein, Christiane ;
Zenker, Martin ;
Mall, Volker .
TRIALS, 2023, 24 (01)
[96]   NK-104: a novel synthetic HMG-CoA reductase inhibitor [J].
Kajinami, K ;
Mabuchi, H ;
Saito, Y .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (11) :2653-2661
[97]   Impact of OATP transporters on pharmacokinetics [J].
Kalliokoski, A. ;
Niemi, M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (03) :693-705
[98]   SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation [J].
Kaplan, David E. ;
Mehta, Rajni ;
Garcia-Tsao, Guadalupe ;
Albrecht, Jeffrey ;
Aytaman, Ayse ;
Baffy, Gyorgy ;
Bajaj, Jasmohan ;
Hernaez, Ruben ;
Hunt, Kristel ;
Ioannou, George ;
Johnson, Kay ;
Kanwal, Fasiha ;
Lee, Tae-Hoon ;
Monto, Alexander ;
Pandya, Prashant ;
Schaubel, Douglas ;
Taddei, Tamar H. .
CONTEMPORARY CLINICAL TRIALS, 2021, 104
[99]   Preventive Effects of Nicorandil and Atorvastatin in Contrast-induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Artery Angiography: A Double Blind, Randomized, Controlled Clinical Trial [J].
Kebar, Sousan Mohammadi ;
Atighi, Elham ;
Hosseninia, Saeed ;
Babapour, Behzad .
IRANIAN JOURNAL OF KIDNEY DISEASES, 2023, 17 (04) :205-214
[100]   Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis [J].
Kennedy, J ;
Auclair, K ;
Kendrew, SG ;
Park, C ;
Vederas, JC ;
Hutchinson, CR .
SCIENCE, 1999, 284 (5418) :1368-1372